P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA. (23rd June 2022) - Xu, Z.; Duan, M.; Jiang, Q.; Leng, Q.; Xu, N.; Zhang, Y.; Zhao, C.; Wu, W.; Zhang, Q.; Fu, J.; Zhang, J.; Fu, R.; et al.